{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-089704","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.154728+00:00","generated_at":"2026-05-31T09:14:48.372460+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Marker Therapeutics Q2 net loss narrows to $2.2M; reports positive MT-601 APOLLO data, receives $2M NIH grant","bullets":["Net loss from continuing ops $2.2M vs $4.1M YoY; cash $7.8M expected to fund into Q4 2025.","MT-601 APOLLO study shows objective responses in 3 of 3 lymphoma patients; no CRS or ICANS observed.","Awarded $2M NIH SBIR grant to support MT-601 lymphoma trial.","MT-401-OTS IND cleared for AML/MDS; clinical program initiation expected Q4 2024.","R&D expenses $2.3M (flat); G&A decreased to $1.1M from $2.5M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-089704","json":"https://secwatch.observer/filing/0001104659-24-089704.json","markdown":"https://secwatch.observer/filing/0001104659-24-089704.md","text":"https://secwatch.observer/filing/0001104659-24-089704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924089704/0001104659-24-089704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924089704/tm2421372d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:14:48.372460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}